デフォルト表紙
市場調査レポート
商品コード
1628898

骨がん治療の世界市場:種類別・治療法別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年~2032年)

Bone Cancer Treatment Market, By Type, By Treatment, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032


出版日
ページ情報
英文 303 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
骨がん治療の世界市場:種類別・治療法別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年~2032年)
出版日: 2024年12月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

骨がん治療の市場規模は、2023年に13億2,150万米ドルとなり、2024年から2032年にかけてCAGR 5.50%で拡大

骨がん治療の市場力学

骨がん罹患率の上昇

骨がんの発生率の上昇により、骨がん治療市場は拡大すると予測されます。骨組織から発生する悪性腫瘍 (がん) は骨がんと呼ばれます。骨細胞が制御不能に成長して分裂し、腫瘍や腫瘤を形成することで発生します。骨がん治療の目的は、患者に多くの利益をもたらすことです。いくつかの骨悪性腫瘍がこの治療法で治療され、手術、四肢温存、疼痛緩和、生活の質の向上、腫瘍の制御などが行われました。例えば、米国の医師を代表する専門組織である米国臨床腫瘍学会 (ASCO) は2023年2月、15歳から19歳の201例のうち、2023年に米国で新たに3,970例 (男性2,160例、女性1,810例) の原発性骨肉腫が診断されると報告しています。このように、骨がん治療市場は骨がんの罹患率の上昇によって牽引されています。

骨がん治療市場:主な考察

当社のリサーチアナリストが共有した分析によると、世界の骨がん治療市場は、予測期間 (2024-2032年) に約5.50%のCAGRで毎年成長すると推定されています。

種類に基づくと、原発性骨がんカテゴリーは2023年に最大の市場シェアを示すと予測されました。

治療法に基づくと、化学療法が2023年の主要セグメントでした。

地域別では、北米が2023年の主要収益源でした。

骨がん治療市場:セグメンテーション分析

骨がん治療の世界市場は、タイプ、治療、エンドユーザー、地域に基づいてセグメント化されます。

タイプ別では、原発性骨がん (ユーイング肉腫、骨肉腫、軟骨肉腫、その他の原発性骨がん) と続発性骨がんに分類されます。原発性骨がんカテゴリーは2023年の市場をリードしました。原発性骨がんは、骨肉腫と呼ばれることもあり、骨で始まり他の臓器に転移しないがんです。このため、体の他の部位から転移した骨がん (しばしば二次性または転移性骨がんとして知られる) とは区別されます。原発性骨がんに対しては、通常、放射線療法、標的治療、四肢温存術などの特殊な治療アプローチが必要となります。また、肺がんや乳がんなどの他のがんに比べ、原発性骨がんは比較的まれです。しかし、その希少性から、その重要性が軽減されるわけではありません。原発性骨がんは発生率が非常に低いため、研究や治療開発の焦点となっています。

治療法別では、標的・免疫療法 (デノスマブ、スニチニブ、イマチニブ、その他の標的・免疫療法)、放射線療法、手術療法、化学療法 (ドキソルビシン、エトポシド、シスプラチン、シクロホスファミド、その他の化学療法) に分類されます。2023年には、化学療法カテゴリーが骨がん治療の世界市場を牽引する存在となりました。化学療法は全身治療であり、血流を通じて体内のあらゆる部位に作用します。この特徴により、元の骨腫瘍だけでなく、転移や臓器転移の可能性のあるがん細胞も標的にすることができます。化学療法は、骨組織のような届きにくい場所にある腫瘍であっても、腫瘍を縮小させるのに非常に効果的です。化学療法は、特に病期が進行している患者さんや転移が著しい患者さんにおいて、骨がんの増殖や転移を抑える上で非常に重要です。手術後、化学療法は術後補助療法として用いられることが多いです。手術後に残ったがん細胞を取り除くことで、原発性骨がんの場合、再発の可能性が低くなります。ネオアジュバント治療 (化学療法) は手術前に行われることもあります。

骨がん治療市場:地域別分析

地域的には、骨がん治療市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

北米の骨がん治療市場は、整備されたヘルスケアインフラ、研究開発の重視、高い医療費によって特徴付けられます。この地域の強力な償還政策と規制構造により、革新的な骨がん治療オプションの開発と採用が奨励されています。北米の多くのバイオテクノロジー企業や製薬企業も、免疫療法、標的治療薬、個別化医療戦略など、骨がんの新しい治療法の創出に積極的に取り組んでいます。また、同地域では特に高齢者の間で骨がんの罹患率が上昇していることから、市場も拡大しています。

予測期間を通じて、アジア太平洋市場は最も速い速度で成長すると予想され、骨がん治療業界の参入企業に大きな成長の見通しをもたらしています。アジア太平洋地域の莫大な人口と拡大する人口などの要因によって、多くの患者が存在することが暗示されています。ヘルスケアへのアクセスが向上するにつれて、骨がん治療のニーズが高まることが予想されます。アジア太平洋諸国では、急速な工業化とライフスタイルの変化により、がん、特に骨がんの患者が増加しています。この傾向は、骨がん治療市場の成長を求めています。この地域は患者数が多く、多様性に富んでいるため、臨床研究の中心地となっています。

骨がん治療市場:競合情勢

骨がん治療市場は、ファイザー、バクスターインターナショナル、アドバクシス、アムジェン、アトラントセラ、バイエルAGなど、多くの競合企業が国内外に進出しているため、非常に細分化されています。市場全体のダイナミクスに貢献する様々な企業が競合情勢を定義しています。この区分は、業界の既存企業、新規参入企業、専門ソリューションサプライヤー間の市場シェア争いに起因します。企業の知名度を高めるために様々な戦術を用いることは、市場プレイヤーの多様性を浮き彫りにします。世界的に、調査対象業界の企業は、積極的な拡大計画を推進することで、戦略的な立場に身を置いています。例えば、Zetagen TherapeuticsのZetaMet技術は、2021年12月に米国食品医薬品局 (FDA) の機器・放射線衛生センター (CDRH) により画期的製品に指定されました。これは、転移性骨疾患の最先端治療としてのゼータメットの有望性を示すものです。これは、審査・開発プロセスを加速させる上で事業の一助となりました。

目次

第1章 骨がん治療市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 骨がん治療の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第5章 骨がん治療市場:COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 骨がん治療の市場情勢

  • 骨がん治療の市場シェア分析 (2023年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 骨がん治療市場:種類別

  • 概要
    • セグメント別シェア分析:種類別
    • 原発性骨がん
      • ユーイング肉腫
      • 骨肉腫
      • 軟骨肉腫
      • その他の原発性骨がん
    • 二次性骨がん

第8章 骨がん治療市場:治療法別

  • 概要
    • セグメント別シェア分析:治療法別
    • 標的・免疫療法
      • デノスマブ
      • スニチニブ
      • イマチニブ
      • その他の標的・免疫療法
    • 放射線治療
    • 手術
    • 化学療法
      • ドキソルビシン
      • エトポシド
      • シスプラチン
      • シクロホスファミド
      • その他の化学療法

第9章 骨がん治療市場:エンドユーザー別

  • 概要
    • セグメント別シェア分析:エンドユーザー別
    • 病院
    • 外来手術センター (ASC)
    • 腫瘍センター・専門クリニック
    • その他

第10章 骨がん治療市場:地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 韓国
    • 日本
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析:骨がん治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • Baxter International Inc.
    • Advaxis Inc.
    • Amgen Inc.
    • Atlanthera
    • Bayer AG
    • Debiopharm
    • Spectrum Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company
    • Johnson &Johnson
    • Gradalis Inc.
    • Eli Lilly and Company
    • Hikma Pharmaceutical PLC
    • Novartis AG
    • Recordati Group
    • Others

第12章 AnalystViewの全方位的分析

目次
Product Code: ANV4431

REPORT HIGHLIGHT

Bone Cancer Treatment Market size was valued at USD 1,321.5 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

When aberrant cells in bone grow out of control, bone cancer occurs. Healthy bone tissue is destroyed in this cancer. Malignant or cancerous bone tumours can occur. Cancer cells can spread throughout the body as a result of malignant bone tumours. Children, teens, and young adults are more likely to experience them than older adults; however, they can appear at any age. Bone cancer can be treated with a variety of methods, including surgery, radiation therapy, chemotherapy, and targeted therapy. The rise in cancer prevalence, the expansion of government efforts, and the spike in product launches and approvals are the main drivers propelling the growth of the bone cancer treatment market. Moreover, a key driver of the market for bone cancer treatments is the rise in bone cancer, particularly osteosarcoma.

Bone Cancer Treatment Market- Market Dynamics

Rising Incidence of Bone Cancer

It is anticipated that the market for bone cancer treatments will expand due to the rising incidence of bone cancer. Malignant (cancerous) tumours that start in bone tissue are referred to as bone cancer. It happens when bone cells grow out of control and divide, creating a tumour or mass. The purpose of bone cancer treatments is to provide patients with a number of benefits. Several bone malignancies were treated with this therapy, which included surgery, limb preservation, pain relief, improved quality of life, and tumour control. For instance, the American Society of Clinical Oncology (ASCO), a professional organization that represents physicians in the United States, reported in February 2023 that 3,970 new cases of primary bone sarcoma (2,160 men and 1,810 women) would be diagnosed in the United States in 2023, out of 201 cases in people aged 15 to 19. Thus, the market for bone cancer treatments is being driven by the rising incidence of bone cancer.

Bone Cancer Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global Bone Cancer Treatment Market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on type segmentation, the primary bone cancer category was predicted to show maximum market share in the year 2023

Based on treatment segmentation, chemotherapy was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Bone Cancer Treatment Market- Segmentation Analysis:

The Global Bone Cancer Treatment Market is segmented on the basis of Type, Treatment, End-user, and Region.

Based on type, the market is categorized into Primary bone cancer (Ewing sarcoma, Osteosarcoma, Chondrosarcoma, Other primary bone cancer) and Secondary bone cancer. The primary bone cancer category led the market in 2023. Primary bone cancer, sometimes referred to as bone sarcoma, is cancer that starts in the bone and does not spread to other organs. This distinguishes it from bone cancer that has spread from other parts of the body, often known as secondary or metastatic bone cancer. Specialized treatment approaches, including radiation therapy, targeted therapies, and limb-sparing procedures, are usually required for primary bone cancer. In addition, compared to other cancers like lung or breast cancer, primary bone cancer is comparatively uncommon. Its scarcity does not, however, lessen its significance. Primary bone cancer is a focus of study and therapeutic development due to its very low incidence.

By treatment, the market is segregated into Targeted and immunotherapy (Denosumab, Sunitinib, Imatinib, Other targeted & immunotherapies), Radiation therapy, Surgery, and Chemotherapy (Doxorubicin, Etoposide, Cisplatin, Cyclophosphamide, Other chemotherapies). In 2023, the chemotherapy category became the leading force in the global market for the treatment of bone cancer. Chemotherapy is a systemic treatment that travels through the bloodstream to all parts of the body. This feature enables it to target cancer cells in the original bone tumour as well as any possible metastases or organ spreads. Chemotherapy works very well in reducing tumours, even ones that are located in difficult-to-reach places like bone tissue. Chemotherapy can be extremely important in limiting the growth and spread of bone cancer, particularly in patients with advanced stages of the illness or significant metastases. Following surgery, chemotherapy is frequently used as an adjuvant treatment. Removing any cancer cells that may have remained after surgery lowers the chance of recurrence in cases of primary bone cancer. Neoadjuvant treatment, or chemotherapy, is sometimes given prior to surgery.

Bone Cancer Treatment Market- Geographical Insights

Geographically, the Bone Cancer Treatment Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for bone cancer treatments in North America is distinguished by its well-developed healthcare infrastructure, substantial emphasis on research and development, and high healthcare spending. Innovative bone cancer treatment options are encouraged to be developed and adopted by the region's strong reimbursement policies and regulatory structure. Many biotechnology and pharmaceutical companies in North America are also actively working on creating new treatments for bone cancer, such as immunotherapies, targeted medicines, and personalized medicine strategies. The market is also growing as a result of the region's rising incidence of bone cancer, especially among the elderly population.

Throughout the projected period, the Asia-Pacific market is expected to grow at the quickest rate, providing participants in the bone cancer treatment industry with significant growth prospects. A significant patient pool is implied by factors like the Asia-Pacific region's enormous and expanding population. It is anticipated that the need for bone cancer treatment will rise as access to healthcare improves. In Asia-Pacific nations, rapid industrialization and changes in lifestyle are causing a rise in cancer cases, particularly bone cancer. This tendency calls for the market for bone cancer treatments to grow. The region's sizable and varied patient population is making it a centre for clinical studies.

Bone Cancer Treatment Market- Competitive Landscape:

The bone cancer treatment market is highly fragmented, mainly because many competitors are operating both locally and globally, such as Pfizer Inc., Baxter International Inc., Advaxis Inc., Amgen Inc., Atlanthera, Bayer AG, and others. Various companies that all contribute to the overall dynamics of the market defines the competitive landscape. This division results from the competition for market share between established industry players, newcomers, and specialist solution suppliers. The use of a variety of tactics to increase the company's visibility highlights the diversity of market players. Globally, businesses in the industry under study are putting themselves in a strategic position by pursuing aggressive expansion plans. For instance, Zetagen Therapeutics' ZetaMet technology was designated a breakthrough product by the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) in December 2021. It demonstrates ZetaMet's promise as a cutting-edge therapy for metastatic bone diseases. This aided the business in accelerating the review and development process.

Recent Developments:

February 2024: Telix declared its intention to purchase QSAM Biosciences, Inc. and its primary experimental medication, Samarium-153-DOTMP (153Sm-DOTMP). A U.S.-based business called QSAM creates therapeutic radiopharmaceuticals for bone cancer, both primary and metastatic. The company was able to expand its clientele and break into unexplored markets thanks to this acquisition.

October 2023: Zetagen Therapeutics released ZetaMet's preliminary clinical study results in the peer-reviewed journal Pain Management. This includes information on ZetaMet's effectiveness and safety in patients with bone metastases.

March 2023: CADD522, a novel medication, was created by researchers at the Universities of Sheffield and East Anglia to treat patients with primary bone malignancies. In preclinical models, this medication increased survival rates by 50%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BONE CANCER TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Baxter International Inc.
  • Advaxis Inc.
  • Amgen Inc.
  • Atlanthera
  • Bayer AG
  • Debiopharm
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company
  • Johnson & Johnson
  • Gradalis Inc.
  • Eli Lilly and Company
  • Hikma Pharmaceutical PLC
  • Novartis AG
  • Recordati Group
  • Others

GLOBAL BONE CANCER TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Primary bone cancer
  • Ewing sarcoma
  • Osteosarcoma
  • Chondrosarcoma
  • Other primary bone cancer
  • Secondary bone cancer

GLOBAL BONE CANCER TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Targeted and immunotherapy
  • Denosumab
  • Sunitinib
  • Imatinib
  • Other targeted & immunotherapies
  • Radiation therapy
  • Surgery
  • Chemotherapy
  • Doxorubicin
  • Etoposide
  • Cisplatin
  • Cyclophosphamide
  • Other chemotherapies

GLOBAL BONE CANCER TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Ambulatory surgical centers (ASCs)
  • Oncology centers & specialty clinics
  • Others

GLOBAL BONE CANCER TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bone Cancer Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bone Cancer Treatment Market Snippet by Type
    • 2.1.2. Bone Cancer Treatment Market Snippet by Treatment
    • 2.1.3. Bone Cancer Treatment Market Snippet by End-user
    • 2.1.4. Bone Cancer Treatment Market Snippet by Country
    • 2.1.5. Bone Cancer Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Bone Cancer Treatment Key Market Trends

  • 3.1. Bone Cancer Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bone Cancer Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bone Cancer Treatment Market Opportunities
  • 3.4. Bone Cancer Treatment Market Future Trends

4. Bone Cancer Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bone Cancer Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bone Cancer Treatment Market Landscape

  • 6.1. Bone Cancer Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bone Cancer Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Primary bone cancer
      • 7.1.2.1. Ewing sarcoma
      • 7.1.2.2. Osteosarcoma
      • 7.1.2.3. Chondrosarcoma
      • 7.1.2.4. Other primary bone cancer
    • 7.1.3. Secondary bone cancer

8. Bone Cancer Treatment Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Targeted and immunotherapy
      • 8.1.2.1. Denosumab
      • 8.1.2.2. Sunitinib
      • 8.1.2.3. Imatinib
      • 8.1.2.4. Other targeted & immunotherapies
    • 8.1.3. Radiation therapy
    • 8.1.4. Surgery
    • 8.1.5. Chemotherapy
      • 8.1.5.1. Doxorubicin
      • 8.1.5.2. Etoposide
      • 8.1.5.3. Cisplatin
      • 8.1.5.4. Cyclophosphamide
      • 8.1.5.5. Other chemotherapies

9. Bone Cancer Treatment Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Ambulatory surgical centers (ASCs)
    • 9.1.4. Oncology centers & specialty clinics
    • 9.1.5. Others

10. Bone Cancer Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bone Cancer Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bone Cancer Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bone Cancer Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bone Cancer Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bone Cancer Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bone Cancer Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Baxter International Inc.
    • 11.2.3. Advaxis Inc.
    • 11.2.4. Amgen Inc.
    • 11.2.5. Atlanthera
    • 11.2.6. Bayer AG
    • 11.2.7. Debiopharm
    • 11.2.8. Spectrum Pharmaceuticals Inc.
    • 11.2.9. Takeda Pharmaceutical Company
    • 11.2.10. Johnson & Johnson
    • 11.2.11. Gradalis Inc.
    • 11.2.12. Eli Lilly and Company
    • 11.2.13. Hikma Pharmaceutical PLC
    • 11.2.14. Novartis AG
    • 11.2.15. Recordati Group
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us